Compare PTIX & AKAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PTIX | AKAN |
|---|---|---|
| Founded | 1994 | 2021 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2M | 1.6M |
| IPO Year | 2016 | 2022 |
| Metric | PTIX | AKAN |
|---|---|---|
| Price | $1.66 | $0.92 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 103.8K | ★ 5.5M |
| Earning Date | 11-26-2025 | 12-23-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $836,664.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 183.67 |
| 52 Week Low | $1.46 | $0.74 |
| 52 Week High | $14.28 | $9.29 |
| Indicator | PTIX | AKAN |
|---|---|---|
| Relative Strength Index (RSI) | 33.67 | 35.40 |
| Support Level | $1.46 | $0.74 |
| Resistance Level | $1.70 | $1.34 |
| Average True Range (ATR) | 0.18 | 0.15 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 20.65 | 28.67 |
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's main compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.
Akanda Corp is a cannabis cultivation, manufacturing, and distribution company. The company has three reportable segments: Cultivation, Distribution, and Corporate. A majority of its revenue is generated from the Distribution segment, which relates to the distribution of medical cannabis products, including cannabis oil and cannabis flower for medical use in the United Kingdom.